- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07591454
Treatment Outcome of Elastomeric and Nickel-Titanium Separators in Tooth Separation
May 13, 2026 updated by: 3D-Aligners
Comparison Between The Efficiency Of Elastomeric And Nickel-Titanium Separators In Tooth Separation, Pain Perception, And Gingival Inflammation - A Randomized Controlled Trial
Patients seeking fixed orthodontic treatment that requires band placement will be enrolled in this study.
This trial aims to compare the efficiency of rectangular cross-section nickel-titanium separators with elastomeric separators in creating sufficient interdental space for orthodontic band placement.
In addition, the impact of both separator types on pain perception and gingival health during a 3-day placement period will be evaluated.
Participants will be allocated to two groups in a split-mouth design.
On the experimental side, nickel-titanium separators will be used, while elastomeric separators will be used as the control on the other side.
Outcomes will include separation efficacy, pain perception over time, gingival inflammation, analgesic consumption, and separator loss.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
In fixed orthodontic therapy, placement of separators is usually the first clinical step to create interdental space between posterior teeth, particularly the first molars, in preparation for orthodontic band placement.
Failure to adequately separate teeth prior to banding may result in enamel damage, distortion of the band material, soft tissue injury, and increased patient discomfort.
Improper band placement without sufficient separation can also lead to excessive pressure on the periodontal ligament (PDL), a risk of alveolar bone contact, and the formation of hyalinized areas within the PDL, evoking a pain response from resident mechanoreceptors.
Pain is one of the primary reasons for patient dissatisfaction and discontinuation of orthodontic treatment.
Therefore, identifying an ideal orthodontic separator that can produce adequate tooth separation while minimizing pain, discomfort, and gingival inflammation is of considerable clinical importance.
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Aghiad Abdalrazzak
- Phone Number: +963931647613
- Email: aghiad900@gmail.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Class I skeletal and dental malocclusion.
- No history of previous orthodontic treatment.
- All permanent teeth in both arches, except third molars.
- Good oral hygiene and periodontal health.
- Good interproximal tooth contacts at the site of separator placement as
- checked by interdental floss.
- No caries or restorations on the proximal surfaces of first and second permanent molars, and second premolars.
Exclusion Criteria:
- Patients presenting with restorations or carious lesions on the proximal surfaces of the first or second molars or the second premolars.
- Patients with uncontrolled gingival or periodontal inflammation.
- Patients with a history of previous orthodontic treatment.
- Patients are skeletally classified as Class II or Class III.
- Patients are currently using opioid analgesics or have chronic pain conditions requiring regular analgesic intake.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Nickle-titanium group
|
application of the Nickel-Titanium separators before application of the orthodontic bands on the first molars
|
|
Active Comparator: elastomeric group
|
application of the elastomeric separators before application of the orthodontic bands on the first molars
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Perception
Time Frame: At 4, 24, 48, and 72 hours after separator placement.
|
Pain perception will be assessed using a Visual Analogue Scale (VAS) and a standardized questionnaire.
Patients will receive a pain perception worksheet containing a 100 mm horizontal VAS line for each side of the mouth.
The scale will range from "no pain" to "worst pain imaginable" and will be completed during rest, biting, chewing, work/school activities, and sleep
|
At 4, 24, 48, and 72 hours after separator placement.
|
|
Separation efficacy
Time Frame: At 72 hours after separator placement, at the time of separator removal
|
Interdental separation will be measured at the time of separator removal using a feeler gauge.
A separation greater than 0.16 mm will be considered sufficient for band placement, while a separation of less than 0.16 mm will be considered insufficient.
|
At 72 hours after separator placement, at the time of separator removal
|
|
Gingival inflammation
Time Frame: At baseline, before separator placement, and immediately before separator removal, 72 hours after separator placement
|
Gingival inflammation will be assessed using the Löe Gingival Index.
Scores will range from Grade 0 (healthy gingiva) to Grade 3 (severe gingivitis with spontaneous bleeding and ulceration).
|
At baseline, before separator placement, and immediately before separator removal, 72 hours after separator placement
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Analgesic usage
Time Frame: At 72 hours after separator placement.
|
Participants may take ibuprofen (400 mg) as needed for pain relief.
Analgesic consumption will be recorded using a standardized patient worksheet, including the time of intake, dosage, and the arch side associated with the pain.
|
At 72 hours after separator placement.
|
|
Separator loss
Time Frame: At 72 hours after separator placement.
|
Separator loss will be recorded clinically at the follow-up visit.
A separator is considered lost if it was absent at the time of scheduled removal.
Loss events are documented for each side separately.
|
At 72 hours after separator placement.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2026
Primary Completion (Estimated)
November 1, 2026
Study Completion (Estimated)
February 1, 2027
Study Registration Dates
First Submitted
March 8, 2026
First Submitted That Met QC Criteria
May 13, 2026
First Posted (Actual)
May 15, 2026
Study Record Updates
Last Update Posted (Actual)
May 15, 2026
Last Update Submitted That Met QC Criteria
May 13, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UDDS-0012-2026PG/SRC1542
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Individual participant data will not be publicly shared because the dataset contains sensitive clinical and radiographic information, and participants did not provide consent for public sharing of individual-level data.
De-identified aggregate results will be reported in the study publication.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.